Multimorbidity and functional status assessment

Current Opinion in HIV and AIDS

Volumn 9, Issue 4, 2014, Pages 386-397

  Guaraldi, Giovanni ^a   Silva, Ana Rita ^b   Stentarelli, Chiara ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Centro Hospitalar e Universitário do Porto   (Portugal)

Author keywords

frailty; functional status assessment; HIV; multimorbidity; polypharmacy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTILIPEMIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADL DISABILITY; AGING; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; FRACTURE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; GENETIC DISORDER; GERIATRIC ASSESSMENT; GERIATRIC DISORDER; GROUPS BY AGE; HEALTH CARE COST; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOTHYROIDISM; INTRAVENOUS DRUG ABUSE; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; MULTIMORBIDITY; OBESITY; OSTEOPOROSIS; PATHOGENESIS; PHENOTYPE; PHYSICAL PERFORMANCE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SMOKING; CHRONIC DISEASE; COMPLICATION; HEALTH STATUS; HIV INFECTIONS;

AGING; CHRONIC DISEASE; COMORBIDITY; HEALTH STATUS; HIV INFECTIONS; HUMANS; PREVALENCE;

EID: 84902251618     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000079     Document Type: Review

References (63)

1. Nobili A. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity 2011; 1:28-44.
2. Fortin M, Lapointe L, Hudon C, Vanasse A. Multimorbidity is common to family practice: is it commonly researched? Can Fam Physician 2005; 51:244-245.
3. Salter ML, Lau B, Go VF, et al. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis 2011; 53:1256-1264.
4. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45:1593-1601.
5. Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr 2012; 61:600-605.
6. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-1126.
7. Drummond MB, Kirk GD, Astemborski J, et al. Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. Int J Chron Obstruct Pulmon Dis 2011; 6:89-95.
8. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIVhepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-972.
9. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747-1750.
10. Yanik EL, Lucas GM, Vlahov D, et al. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol 2010; 5:1836-1843.
11. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-1139.
12. Chu C, Umanski G, Blank A, et al. Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx. NY J Urban Health 2011; 88:507-516.
13. J. Schouten, F. W. Wit, I. G. Stolte, et al. Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study. 19th International AIDS Conference: Abstract no. THAB0205. Available from: http://www. iasociety. org/Abstracts/ A200746311. aspx
14. A Prospective, Observational Study to Examine the Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty' (POPPY). Available from: http://clinicaltrials. gov/show/NCT01737047.
15. Justice A. HIV Associated Non AIDS (HANA) Conditions and Inflammation. Denver: American Conference for the Treatment of HIV; 2011.
16. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128:92-105.
17. Macaulay R, Akbar AN, Henson SM. The role of the T cell in age-related inflammation. Age (Dordrecht, The Netherlands) 2013; 35:563-572.
18. Avelino-Silva VI, Ho YL, Avelino-Silva TJ, Santos Sde S. Aging and HIV infection. Ageing Res Rev 2011; 10:163-172.
19. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7:4-10.
20. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
21. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
22. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-983.
23. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
24. Guaraldi G, Luzi K, Bellistri GM, et al. CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients. J Acquir Immune Defic Syndr 2013; 64:360-366.
25. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for healthcare, research, and medical education: a cross-sectional study. Lancet 2012; 380:37-43.
26. Thorpe KE, Howard DH. The rise in spending among Medicare beneficiaries: the role of chronic disease prevalence and changes in treatment intensity. Health Aff (Millwood) 2006; 25:w378-w388.
27. Mangin D, Heath I, Jamoulle M. Beyond diagnosis: rising to the multimorbidity challenge. BMJ 2012; 344:e3526.
28. Justice AC, Landefeld CS, Asch SM, et al. Justification for a new cohort study of people aging with and without HIV infection. J Clin Epidemiol 2001; 54 (Suppl 1):S3-S8.
29. Guaraldi G. Morbidity in older HIV-infected patients: impact of long-term antiretroviral use. AIDS Rev 2014; 16:. [Epub ahead of print]
30. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012; 60 (Suppl 1):S1-18.
31. Martin J, Volberding P. HIV and premature aging: A field still in its infancy. Ann Intern Med 2010; 153:477-479.
32. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542-553.
33. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2013. [Epub ahead of print]
34. FP7-COBRA Co Morbidity in Relation to AIDS [cited 2014 27/02/2014]. Available from: http://fp7-cobra. eu/.
35. Greenberg RS, Flanders WD, Eley JW, Boring JR. Variability & bias. In: Medical epidemiology. 4th ed New York: Lange; 2004.
36. Global Health and Aging. World Health Organization, 2011 NIH Publication no. 11-7737.
37. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Guidelines]. AIDSinfo website2013 [cited 2014 09 APR]. Available from: http://aidsinfo. nih. gov/guidelines.
38. European AIDS Clinical Society Guidelines: European AIDS Clinical Society (EACS); 2013 [updated October 2013; cited 2014 09 APR]. Guidelines]. Available from: http://www. eacsociety. org/Portals/0/Guidelines-Online 131014. pdf.
39. Writing Group. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. HIV MedV 15 2014; 1-85.
40. Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiologica 2012; 35:113-159.
41. Gleason LJ, Luque AE, Shah K. Polypharmacy in the HIV-infected older adult population. Clinical interventions in aging 2013; 8:749-763.
42. Guaraldi G, Zona S, Menozzi M, et al. Cost of noninfectious comorbidities in patients with HIV. Clinicoecon Outcomes Res 2013; 5:481-488.
43. Justice A. Overview of Ageing: a. How Can We Optimize Care in the Context of Multimorbidity? Amy C. Justice, MD, PhD Professor, Yale University. Schools of Medicine. 2011.
44. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol 2001; 51:615-622.
45. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 2008; 31:545-556.
46. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med 2012; 28:237-253.
47. Lin CF, Wang CY, Bai CH. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study. Drugs Aging 2011; 28:219-225.
48. Secoli SR, Figueras A, Lebrao ML, et al. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging 2010; 27:759-770.
49. Tamura BK, Bell CL, Inaba M, Masaki KH. Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med 2012; 28:217-236.
50. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008; 299:1922-1928.
51. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365:2002-2012.
52. Miller RR. Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med 1974; 134:219-223.
53. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997; 315:1096-1099.
54. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010; 24:2705-2715.
55. Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med 2007; 23:567-583; vii.
56. Mandalia S, Mandalia R, Lo G, et al. Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS One 2010; 5:e15677.
57. Elsawy B, Higgins KE. The geriatric assessment. Am Fam Physician 2011; 83:48-56.
58. Erlandson KM, Allshouse AA, Jankowski CM, et al. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials 2012; 13:324-334.
59. Greene M, Valcour V, Miao Y, et al. Geriatric syndromes are common among older HIV-infected adults: in this group over age 50, 50% of participants had frailty or prefrailty ay higher frequencies than HIV-negatives 21st Conference on Retroviruses and Opportunistic Infections2014 [cited 2014 18/03/2014]. Available from: http://www. croiwebcasts. org/console/player/22199?media Type=audio&.
60. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-M156.
61. Mitnitski A, Song X, Rockwood K. Assessing biological aging: the origin of deficit accumulation. Biogerontology 2013; 14:709-717.
62. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013; 381:752-762.
63. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and antiretroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010; 208:222-227.